# A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

> **NCT05898620** · PHASE3 · RECRUITING · sponsor: **Neurogene Inc.** · enrollment: 33 (estimated)

## Conditions studied

- Rett Syndrome

## Interventions

- **GENETIC:** NGN-401

## Key facts

- **NCT ID:** NCT05898620
- **Lead sponsor:** Neurogene Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05898620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05898620, "A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05898620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*